As we verified the angiogenic potential of CXCL2 and IL8, implying an involvement of the CXCR2 axis in tumor angiogenesis, we aimed to investigate the effect of CXCR2 antagonist SB225002 on primary human endothelial cells. This evidence concerns the gene CXCL2 and neoplasm.